Sofinnova Partners Fund IV

Sofinnova Partners

cb Email

Status

ACTIVE

Global HQ

Paris, France

Countries of investment

France
Italy
United Kingdom
Germany
Switzerland
Netherlands
Belgium
Ireland
Spain
Denmark
Sweden
United States

Investment stages

Pre-Seed
Seed

Industries

MedTech
Medical Devices

About
Sofinnova Partners is a Paris-based life sciences venture capital firm with offices in London and Milan. MD Start IV invests across France, Italy, the United Kingdom, Germany, Switzerland, the Netherlands, Belgium, Ireland, Spain, Denmark, Sweden and the United States. The fund supports founders at pre-seed and seed stages and closed at €82M.

Min check size: $1M
Max check size: $5M
Fund size: Unlock
NPS: Unlock

Investment Thesis

Sofinnova MD Start is a medtech acceleration fund that creates and finances early-stage companies developing breakthrough therapeutic medical devices. It works directly with clinicians to turn innovative ideas into companies, combining company building with seed-stage capital. The fund differentiates itself through a team of serial medtech entrepreneurs and Sofinnova Partners' long record in European life sciences.

Lead investor: Unlock
Co Invest: Unlock
Number of exits: Unlock
Preferred contact method: Unlock

Manager's Experience

Sofinnova Partners was founded in 1972 in Paris, France, has offices in London and Milan, and has backed more than 500 life sciences companies. The MD Start strategy is led by Partners Anne Osdoit, Cécile Dupont and Mano Iyer, a team of serial medtech entrepreneurs, with Gérard Hascoët as Venture Partner and Antoine Papiernik as firm Chairman and Managing Partner. MD Start has created and financed companies including Moon Surgical, SafeHeal, CorWave, LimFlow and preCARDIA, which was acquired by Abiomed. MD Start IV closed at €82M, following the €63M MD Start III.